Immunotherapy before surgery for head and neck tumors reduces risk of recurrence


Immunotherapy before surgery for late-stage mouth and throat cancer to prevent recurrence of the condition is safe and effective, according to the results of a trial conducted at the Netherlands Cancer Institute, led by head and neck surgeon Lotje Zuur. The results were published on December 22 in Nature Communications.

Joris Vos et al., ‘Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma’, the IMCISION-trial, Nature Communications 22-12-2021.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.